Phase 2 Glaucoma Trial, Recruiting (NCT06991712)

Phase 2 Glaucoma Trial, Recruiting NCT06991712 Sponsor: Christopher Kai Shun Leung Condition: Glaucoma

Printed from Voxsanity (voxsanity.com.au) — NCT06991712 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Glaucoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with glaucoma
You are 18 years of age or older
Your vision (with glasses or contacts if needed) is 20/40 or better
Your eye pressure is below 21 mmHg (within the normal range)
Your visual field (side vision) test results show only mild to moderate loss, not severe damage

Who may not be able to join:

You have an unusually high level of nearsightedness classified as "pathological" (confirm with trial site)
You have another condition (besides glaucoma) that affects your vision or the appearance of your optic nerve
You are unable to complete a reliable eye field vision test
The eye scan (OCT) images taken of your eyes are not clear enough to use
You have diabetic damage to your retina or the central part of your eye (macula)
You have had abnormal liver function test results in the past 12 months
You have a known allergy to NAD precursor supplements (a type of nutritional supplement) (confirm with trial site)
You are currently pregnant or breastfeeding
You have taken NAD precursor supplements within 14 days before the start of the trial

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Christopher Kai-shun LEUNG, MD, The University of Hong Kong

Phone: (852)3910-2673

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06991712

Sponsor: Christopher Kai Shun Leung

Phase: Phase 2

Status: Recruiting

Condition: Glaucoma

Trial contact: (852)3910-2673

More information: https://clinicaltrials.gov/study/NCT06991712

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with glaucoma
You are 18 years of age or older
Your vision (with glasses or contacts if needed) is 20/40 or better
Your eye pressure is below 21 mmHg (within the normal range)
Your visual field (side vision) test results show only mild to moderate loss, not severe damage

Who may not be able to join:

You have an unusually high level of nearsightedness classified as "pathological" (confirm with trial site)
You have another condition (besides glaucoma) that affects your vision or the appearance of your optic nerve
You are unable to complete a reliable eye field vision test
The eye scan (OCT) images taken of your eyes are not clear enough to use
You have diabetic damage to your retina or the central part of your eye (macula)
You have had abnormal liver function test results in the past 12 months
You have a known allergy to NAD precursor supplements (a type of nutritional supplement) (confirm with trial site)
You are currently pregnant or breastfeeding
You have taken NAD precursor supplements within 14 days before the start of the trial

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Christopher Kai Shun Leung

Registry

ClinicalTrials.gov

Start date

19 May 2025

Est. completion

31 December 2025

Where this trial is recruiting

Hong Kong

Primary endpoints

Change in visual field sensitivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov